TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03277170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast Oral Granules
Description: Montelukast granules, 30 mg, mixed with applesauce

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast Oral Granules
Description: Montelukast granules, 30 mg, mixed with applesauce
Study: NCT04005209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: The experimental group will receive a ketamine intravenous infusion, initiated at 0.2 mg/kg/hr within the first 12 to 24 hours on an inpatient admission for sickle cell pain crisis, and titrated per hospital policy by the inpatient pain service.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain management
Description: Pain management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain management
Description: Pain management
Study: NCT05946135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: taking lansoprazole + placebo for Fexuprazan Hydrochloride for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexuprazan Hydrochloride
Description: taking placebo for lansoprazole + Fexuprazan Hydrochloride for 4 weeks
Study: NCT05725057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AX-158
Description: Subjects randomized to this arm will receive AX-158 treatment for 28 days with a 30 day safety follow-up period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to this arm will receive placebo treatment for 28 days with a 30 day safety follow-up period.
Study: NCT04802876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Spartalizumab (PDR001) 400mg will be given intravenously every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Spartalizumab (PDR001) 400mg will be given intravenously every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 300mg will be given intravenously every 28 days
Study: NCT05723549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1803-3
Description: Take it once per period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD2002
Description: Take it once per period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCP1904-1
Description: Take it once per period
Study: NCT06697678

Intervention type: OTHER
Intervention: No Intervention: Observational Cohort
Description: No intervention

Intervention type: OTHER
Intervention: No Intervention: Observational Cohort
Description: No intervention
Study: NCT06700044

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GutMagnific
Description: Participants will take one stick/10\^9 CFU of probiotic dietary supplement GutMagnific per day from gestational week 12 until gestational week 37

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GutMagnific
Description: Participants will take one stick/10\^9 CFU of probiotic dietary supplement GutMagnific per day from gestational week 12 until gestational week 37

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take one stick/placebo per day from gestational week 12 until partus.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take one stick/placebo per day from gestational week 12 until partus.
Study: NCT06704191

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Solution
Description: Given intravesically

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystoscopy
Description: Undergo cystoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given intravesically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given intravesically
Study: NCT06619639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social-emotional learning curriculum
Description: EMPOWER is a 16-week social-emotional learning curriculum that is integrated into the after-school program context.
Study: NCT06704191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Health Encounter
Description: Receive access to CCBW home health visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: Given intravesically
Study: NCT06129162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional Syringe
Description: Dental local anesthesia injection is given by conventional syringe by two injection methods inferior alveolar nerve block and buccal infiltration.
Study: NCT06627426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR-based patient informed consent
Description: The intervention group will be the on receiving VR-based patient informed consent. One surgeon from the study team will be guiding the patient through their VR model first with demonstration of the technology and the model, afterwards the patient will be enabled to use the VR system by themselves. During the whole process the patient will be able to ask questions. Depending on the planned surgery, the surgical approach as well important anatomical structures will be explained.
Study: NCT06628453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM
Description: Real-time continuous glucose monitoring
Study: NCT06630351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Counseling
Description: Participate in MCP-C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Participate in virtual group discussions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Receive reading exercises and workbook materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05632068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xian-Hua-Cha
Description: Zizyphus jujuba Mill., Nelumbo nucifera Gaertn, Citrus reticulata Blanco, Rosa rugosa Thunb., Cassia obtusifolia L., Stevioside, resistant starch, and water
Study: NCT06406101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Floor
Description: Uninterrupted 2-minute chest compressions on a manikin that has been moved from the bed to the floor in a simulated scenario of out-of-hospital cardiac arrest

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bed
Description: Uninterrupted 2-minute chest compressions on a manikin that is laying on bed in a simulated scenario of out-of-hospital cardiac arrest
Study: NCT05903027

Intervention type: DRUG
Intervention: Rimegepant 75 MG Disintegrating Oral Tablet
Description: Patients using Rimegepant 75 mg orally disintegrating tablet to treat acute migraine attacks

Intervention type: DRUG
Intervention: Rimegepant 75 MG Disintegrating Oral Tablet
Description: Patients using Rimegepant 75 mg orally disintegrating tablet to treat acute migraine attacks
Study: NCT05567952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nirmatrelvir
Description: Participants will receive 2 tablets of nirmatrelvir every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Participants will receive 1 capsule of ritonavir every 12 hours

Intervention type: DRUG
Group type: OTHER
Intervention: ritonavir
Description: Participants will receive 1 capsule of ritonavir every 12 hours

Intervention type: DRUG
Group type: OTHER
Intervention: placebo for nirmatrelvir
Description: Participants will receive 2 tablets of placebo for nirmatrelvir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
Study: NCT05216419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Since the concentration of D-mac 30,000 IU in the body reaches the maximum in the body around 1 to 3 weeks after administration, the drug is taken once 15 days before the surgery so that the vitamin D3 concentration is maximized at the time of surgery.~In the case of the control group, there is no drug to be taken.
Study: NCT05994014

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET/CT
Description: Experimental test for detecting atherosclerosis
Study: NCT06704191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06706440

Intervention type: OTHER
Intervention: no intervention, observational study
Description: Only data will be taken of patient's file.
Study: NCT06707142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBD11
Description: TBD11 will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally.
Study: NCT06716190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3731579
Description: BI 3731579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3731579
Description: BI 3731579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3731579
Description: BI 3731579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3731579
Description: BI 3731579

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 3731579
Description: Placebo matching BI 3731579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam
Study: NCT04985955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib tablet will be administered orally.
Study: NCT06345963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active H-coil delivered rTMS
Description: Multiple trains of rTMS in a day, for multiple days.
Study: NCT05424133

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High frequency chest wall oscillation
Description: High frequency chest wall oscillations at 13-15Hz oscillating frequency for 20 minutes twice a day for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active cycle of breathing
Description: Active cycle of breathing technique and it will performed twice a day for 4 week intervention period for 20 minutes
Study: NCT06716190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Midazolam
Study: NCT06717776

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Compensation Based Problem Solving Therapy
Description: Compensation-Based Problem Solving Therapy (CB-PST) is a therapeutic approach based on the occupational adaptation model. It entails the implementation of compensatory strategies with the objective of enhancing the performance of both extremities in daily life activities. The therapy encompasses the implementation of problem-solving training.~The occupational problem is defined.~The development of compensation-focused strategies is based on the personal factors and occupational environment identified as relevant to the problematic occupation, as determined according to the principles of the occupational adaptation model.~Once a compensatory strategy has been selected, the next step is to apply it and evaluate its efficacy, with the expectation that an adaptive response will be observed, and that the resulting adaptation will be reflected in improved occupational performance, as guided by the occupational adaptation model.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard rehabilitation
Description: The standard rehabilitation program is provided to all individuals in the inpatient service on an equal basis. The program allows individuals to utilize the physiotherapy and occupational therapy units on a weekly basis, with access available on weekdays. These units are staffed by physiotherapists and occupational therapists. All individuals included in the study received the same service from the same therapists at the same times in a homogeneous manner. All individuals received physiotherapy, electrotherapy, and hydrotherapy as part of this service. In the physiotherapy unit, the first intervention was 25 minutes of electrotherapy for the upper extremity. This was followed by 40 minutes of physiotherapy exercises, conducted with the assistance of a physiotherapist. The final component of the physiotherapy unit programme was 15 minutes of hydrotherapy. In the occupational therapy unit, a standard 40-minute occupa

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard rehabilitation
Description: The standard rehabilitation program is provided to all individuals in the inpatient service on an equal basis. The program allows individuals to utilize the physiotherapy and occupational therapy units on a weekly basis, with access available on weekdays. These units are staffed by physiotherapists and occupational therapists. All individuals included in the study received the same service from the same therapists at the same times in a homogeneous manner. All individuals received physiotherapy, electrotherapy, and hydrotherapy as part of this service. In the physiotherapy unit, the first intervention was 25 minutes of electrotherapy for the upper extremity. This was followed by 40 minutes of physiotherapy exercises, conducted with the assistance of a physiotherapist. The final component of the physiotherapy unit programme was 15 minutes of hydrotherapy. In the occupational therapy unit, a standard 40-minute occupa
Study: NCT06727734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Description: Levonorgestrel 1.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piroxicam
Description: Piroxicam 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal Acetate
Description: Ulipristal 30 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo - LNG
Description: Placebo of levonorgestrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo - Piroxicam
Description: Placebo of piroxicam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - UPA
Description: Placebo of ulipristal acetate
Study: NCT06726122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Profound Matrix
Description: Treatment visits are limited to up to three (3) study treatments (with treatment intervals 6 weeks ± 2 weeks).
Study: NCT06733155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial intervention
Description: Participants completing the mammogram within the study end date will receive a $10 voucher.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lottery intervention
Description: Participants completing the mammogram within the study end date will receive achance to win a $5000 lottery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Messages
Description: Participants will receive a less than 5 minute long video from an influential person. The video will be available in four languages (English, Chinese, Malay, Tamil).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personal Health Concierge
Description: Participants will be able to call a dedicated hotline for scheduling mammograms with the help of a health concierge over eight weeks of receive the the mailer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Only reminder mailer
Description: Receives a mail reminder with basic information about breast cancer and instructions on scheduling a mammogram.
Study: NCT06736379

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection)
Description: Weekly IT injections of 1 x 10\^9 viral particles of VLPONC-01

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection)
Description: Weekly IT injections of 1 x 10\^9 viral particles of VLPONC-01

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection)
Description: Weekly IT injections of 1 x 10\^9 viral particles of VLPONC-01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA®)
Description: 200mg twice 3 weeks apart IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA®)
Description: 200mg twice 3 weeks apart IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA®)
Description: 200mg twice 3 weeks apart IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection)
Description: Weekly IT injections of 3 x 10\^8 viral particles of VLPONC-01
Study: NCT06739616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AUTOSIB across time
Description: Intervention will be in place across increasing time frames.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AUTOSIB diminished reinforcement
Description: Intervention will be in place with decreasing levels of reinforcement
Study: NCT06129162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional Syringe
Description: Dental local anesthesia injection is given by conventional syringe by two injection methods inferior alveolar nerve block and buccal infiltration.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STA Single Tooth Anesthesia® System.
Description: Dental local anesthesia injection is given by STA device by two injection methods inferior alveolar nerve block and buccal infiltration.
Study: NCT06744868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THDBH120 injection (SAD)
Description: Participants received escalating single doses of THDBH120 by subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of THDBH120 injection (SAD)
Description: Participants received single dose of placebo by subcutaneous injection.
Study: NCT06129162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STA Single Tooth Anesthesia® System.
Description: Dental local anesthesia injection is given by STA device by two injection methods inferior alveolar nerve block and buccal infiltration.
Study: NCT04885491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride (placebo)
Description: Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDNO
Description: PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
Study: NCT05337527

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beetroot juice
Description: Acute effects of beetroot juice or placebo juice ingestion

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: beetroot juice
Description: Acute effects of beetroot juice or placebo juice ingestion
Study: NCT05241015

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Treatment protocol; It will be applied to improve posture, strengthen muscles, eliminate shortness, increase flexibility, balance/coordination, sit up/stand up and in-bed mobilization, and improve gait. Before taking the treatment, a general evaluation will be made and as a result of this evaluation, muscle shortness, loss of strength, postural disorders and the activities and positions they have the most difficulty in daily life will be determined. Treatment programs will be shaped according to the problems determined in line with the evaluations made.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises Group
Description: In addition to the standard physiotherapy program, sensorimotor training including the cervical region will be given to the this group. Deep cervical flexor and extensor muscles, which provide stability in the cervical region, will be trained. A Pressure Biofeedback Device will be used to train the deep cervical flexors. Both positional and kinesthetic sensory training will be provided by maintaining the stability of the cervical region by means of the laser kit that provides visual feedback.Additionally, oculomotor exercises will be given.
Study: NCT05841550

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG01
Description: All participants will receive the same treatment as described under arm
Study: NCT06055673

Intervention type: GENETIC
Intervention: DNA extraction AND Real- time polymerase chain reaction analysis to POLYMORPHISM OF in in-stent restenosis (ISR) in CAD
Description: Real- time polymerase chain reaction a gene polymorphism in in-stent restenosis (ISR) in CAD.

Intervention type: GENETIC
Intervention: DNA extraction AND Real- time polymerase chain reaction analysis to POLYMORPHISM OF in in-stent restenosis (ISR) in CAD
Description: Real- time polymerase chain reaction a gene polymorphism in in-stent restenosis (ISR) in CAD.
Study: NCT05259904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: 7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7 weeks of treatment with orally administered matching placebo (to 15 g/day of L-citrulline)